Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Eli Lilly & Co. : Lilly to Discontinue Late-Stage Tabalumab RA Program on Lack of Efficacy

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/07/2013 | 07:59pm CEST

--Lilly to discontinue rheumatoid arthritis Phase 3 program for tabalumab

--Company will take a first-quarter charge of about $50 million

--Tabalumab continues to be in Phase 3 development for systemic lupus, and in Phase 2 development for multiple myeloma.

(Updates with additional details, share movement)

 
   By Saabira Chaudhuri 
 

Eli Lilly & Co. (LLY) said it will discontinue the rheumatoid arthritis Phase 3 program for its drug, tabalumab, citing a lack of efficacy.

The announcement comes less than two months after the drug company said it would stop one of three late-stage registration studies of tabalumab due to insufficient efficacy. At the time, Lilly said it was continuing to evaluate tabalumab in two other Phase 3 rheumatoid-arthritis registration studies as well as an open-label extension study and several smaller studies.

Lilly on Thursday said it has decided to discontinue the development of tabalumab in its current rheumatoid-arthritis program based on the outcomes of two separate interim-futility analyses. All ongoing Phase 2 and Phase 3 rheumatoid-arthritis studies will be stopped.

"While we are obviously disappointed by these results in rheumatoid arthritis, we continue to believe that tabalumab could have significant potential for patients in other disease areas," said Dr. Eiry Roberts, vice president of autoimmune product development at Lilly.

The decision is expected to result in a first-quarter charge to research-and-development expenses of about $50 million.

A spokesperson for the company noted Tabalumab is still in Phase 3 development for systemic lupus, and in Phase 2 development for multiple myeloma.

The Indianapolis company is experiencing one of the steepest patent cliffs in the drug industry, grappling with recent and looming generic competition for top-selling drugs as a result of patent expirations. The company lost exclusivity for its former No. 1 product, Zyprexa, in October 2011, and it will lose U.S. patent protection for the blockbuster antidepressant Cymbalta this December.

Lilly is trying to replenish revenue lost to generic competition for the older drugs by bringing new products to market and by increasing sales of drugs that remain patent-protected.

Last month, Lilly said its fourth-quarter earnings slipped 3.6% as the drug maker recorded weaker revenue as sales of Zyprexa slid.

Shares of Lilly, which backed its view for the year, edged down 41 cents to $53.52 in recent trading. The stock has risen 36% in the past 12 months.

Write to Saabira Chaudhuri at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ELI LILLY AND COMPANY
06/22 ELI LILLY AND : New Non-Small Cell Lung Cancer Data Have Been Reported by Invest..
06/22 ELI LILLY AND : Jardiance® empagliflozin tablets to be studied in chronic kidney..
06/22 ELI LILLY AND : New Safety and Long-Term Efficacy Data from Baricitinib Clinical..
06/22 ELI LILLY AND : Lilly to Present New Data on Olumiant® baricitinib in Rheumatoid..
06/22 ELI LILLY AND : Jardiance® empagliflozin analysis reinforces established safety ..
06/22 ELI LILLY AND : Discovering More Ways to Treat Rare Disease
06/21 ELI LILLY AND : LILLY ELI & CO Submission of Matters to a Vote of Security Holde..
06/21 ELI LILLY AND COMPANY : Unveils Expanded Biotechnology Center in San Diego
06/19 DAILY DIVIDEND REPORT : Lly, bxp, wsm, rl, ai
06/19 ELI LILLY AND : Former FBI Director Cautions Against Drug Importation
More news
Sector news : Pharmaceuticals - NEC
06/22 GSK'S NEW CEO AIMS TO DIVEST SPORTS : sources
06/22 MYLAN : shareholders vote against executive pay, re-elect board
06/22 Health stocks help European equities cut losses
06/22DJR. JOHNSON : Missouri Sues Drug Firms Over Opioid Marketing -- WSJ
06/21DJJOHNSON & JOHNSON : J&J Seeking Dismissal of Talc Lawsuits in Missouri
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
06/22 Drug stocks rally on GOP draft of healthcare bill
06/21 Biotechs blaze as Trump draft order on drug prices would ease regulations
06/21 Lilly completes $90M expansion of California biotech facility
06/21 Biotechs ripping, IBB up almost 8% in three days
06/21 FDA aims at removing barriers to generic drug competition
Advertisement
Financials ($)
Sales 2017 22 083 M
EBIT 2017 5 509 M
Net income 2017 3 246 M
Debt 2017 4 830 M
Yield 2017 2,53%
P/E ratio 2017 31,24
P/E ratio 2018 20,71
EV / Sales 2017 4,35x
EV / Sales 2018 4,26x
Capitalization 91 181 M
More Financials
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | LLY | US5324571083 | 4-Traders
Full-screen chart
Technical analysis trends ELI LILLY AND COM...
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 89,0 $
Spread / Average Target 7,7%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Derica W. Rice Chief Financial Officer & EVP-Global Services
Jan M. Lundberg Executive Vice President-Science & Technology
Kathi P. Seifert Independent Director
Franklyn G. Prendergast Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY12.36%91 303
JOHNSON & JOHNSON16.50%361 566
ROCHE HOLDING LTD.8.81%224 305
NOVARTIS7.69%214 091
PFIZER4.31%199 854
MERCK AND COMPANY11.19%176 500
More Results